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cells in more detail and to further test their functions in 
vitro and in in vivo xenograft models of glioma.
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Introduction
Mesenchymal stromal cells (MSC) are found in a variety 
of tissues where they constitute a stem cell pool [1]. They 
can be mobilized to sites of inflammation and angiogenesis, 
such as wounded tissue and, importantly, various solid can-
cers [2–4]. No single MSC-specific marker exists for in vivo 
detection of this cell type and it has been shown that the 
marker expression of MSCs greatly depends on the tissue in 
which they reside [5, 6]. Human MSCs are defined accord-
ing to in vitro consensus criteria developed by The Interna-
tional Society for Cellular Therapy (ISCT); in culture, MSC 
should adhere to plastic, they should express CD73, CD90, 
CD105 but lack expression of CD11b or CD14, CD19 or 
CD79α, CD34, CD45 and HLA-DR, and they should be 
able to differentiate into adipocytes, osteoblasts and chon-
drocytes [7].
MSC constitute a promising vector system for cell medi-
ated gene therapy [8] as the  display inherent tumor-tropic 
migratory capabilities [9, 10 ] are found in several adult tis-
sues [1] and are easy to isolate and expand in vitro [11 ]. 
However the use of MSCs as a tumor-tropic cellular vec-
to  system in cancer including brain tumor gene therapy 
also raise several concerns as it is not clarified how the 
cells af ect the tumor and its microenvironment [12]. Con-
sequently the presence and role of endogenous in human 
brain umors has now gained attention [13 ]. Isolation of 
glioma-associated human MSCs was recently performed. 
Abstract Gene profiling has revealed that malignant 
gliomas can be divided into fou  dist ct molecular sub-
types, where tumors with a mesenchymal gene expression 
are correlated with short survival. The present investiga-
tion was undertaken to clarify whether human malignant 
gliomas contain endogenous mesenchymal stromal cells 
(MSC), fulfilling consensus criteria defined by The Inter-
national Society for Cellular Therapy, recruited from the 
host. We found that MSC-like cells can be isolated from 
primary human malignant gliomas. Two distinct MSC-like 
cell populations, differing in their expression of the CD90
surface marker, were discover d after cell s rtin . RNA 
sequencing revealed further genetic differences between 
these two cell populations and MSC-like c lls lack ng
CD90 produced higher amounts of VEGF and PGE2 com-
pared to cells with the true MSC ph notyp , implying that 
the CD90− MSC-like cells most probably are more active 
in tumor vascularization and immunosupp ession than their 
CD90 + counterpart. The results highlight the CD90− sub-
population as an important tum r componen , however, its 
functional effects in glioma remains to be olved. Using 
the protocols presented here, it will be possibl  to isolate, 
characterize and analyze brain umor-d ived MSC-like
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(HIB19), FITC-CD34 (581), FITC-CD45 (HI30) and 
FITC-HLA-DR (G46-6, all from BD Biosciences) and iso-
type matched controls for 30 mi  at 4 °C. TO-PRO-1 (Life 
Technologies) was used as viability marker and cells were 
analyzed and sorted on a FACSAria III cell sorter (BD Bio-
sciences, Heidelberg, Germany).
Cell sorting
Culture-derived cells analyzed on the FACSAria III cell 
sorter were simultaneously sorted based on surface marker 
expression. Two populations were sorted from each tumor, 
one expressing the defined MSC phenotype and one 
expressing the defined MSC phenotype except CD90. Cells 
were sorted at passage 2–4 and immediately put back in 
culture.
“In vitro” differentiation
Sorted tumor-derived stromal cells at passage 8–11 were 
used for in vitro differentiation assays. Bone marrow-
derived (BM) MSCs from healthy donors were used as 
positive control and the experiments were performed as 
described elsewhere [14].
For adipocyte differentiation, cells were cultured in 
StemMACS AdipoDiff Media (Miltenyi Biotec) for 14 
days. They were fixed with 4 % formaldehyde solution 
(APL, Stockholm, Sweden) for 60 min at and then incu-
bated in 60 % isopropanol (VWR International, Stockholm, 
Sweden) for 5 min before being stained with 0.18 % Oil Red 
O (Sigma-Aldrich) for 5 min, all at room temperature (RT).
For osteoblast differentiation, cells were cultured in 
osteoblast induction medium for 21 days. They were incu-
bated in ice-cold 70 % ethanol for 1 h at 4 °C before being 
stained with 40 mM Alizarin Red solution (Sigma-Aldrich) 
for 10 min at RT.
For chondrocyte differentiation, cell pellets were grown 
in chondrogenesis induction medium for 28 days. They were 
fixed in Stefanini’s fixative [15 ] and then incubated in 20 % 
sucrose solution (Merck KGaA, Darmstadt, Germany), both 
at 4 °C overnight. The pellets were frozen in Tissue-Tek 
O.C.T. Compound (Sakura Finetek Sweden AB, Göteborg, 
Sweden). 5 µm thick cryosections were permeabilized and 
blocked with PBS supplemented with 0.3 % Triton X-100, 
0.1 % sodium azide, 0.1 % fish skin gelatin (all from Sigma-
Aldrich) and 10 % normal donkey serum (Jackson Immu-
noResearch Europe Ltd., Suffolk, United Kingdom) for 
45 min at RT. They were stained with polyclonal goat anti-
human aggrecan antibody (5 µg/ml, R&D Systems) at 4 °C 
overnight and then Alexa Fluor 594 donkey anti-goat IgG 
(5 µg/ml, Life Technologies) for 60 min at RT. Nuclei were 
visualized by incubation with Hoechst 33342 (8.1 µM, Life 
Technologies) for 15 min at RT.
Analysis of bulk cultures of primary dissociated tissue from 
human glioma revealed that glioma-associated MSCs were 
nontumorigenic stromal cells with phenotypica  similari-
ties to bone marrow-derived human MSCs [13 ]. Genomi  
sequencing of the glioma-associat MSCs suggested that 
most MSCs were normal non-transform d c lls recruited 
into the glioma.
The present investigation wa  undertaken in order to 
expand on these previous recent findings. For this, a robust 
protocol for the detection of MSCs using 9 phenotypic 
markers according to the full ISCT consen us criteria has 
been developed. Following single cell sorting, we here 
report the findings of two distinct populations of glioma-
derived MSC-like cells that differ in their CD90 expression, 
their gene expression pattern and their production of pro-
angiogenic VEGF and immune-suppressive PGE2.
Materials and methods
Tumor samples
Fourteen primary brain tumor samples were obtai ed from 
the neurosurgery department at Skån  University Hospital 
in Lund, Sweden. Ethical permit H15 642/2008. The tis-
sue was washed in phosphate buffered saline (PBS, Life 
Technologies, Carlsbad, CA, USA), placed in a Petri dish 
with StemMACS MSC Expansion Media (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and minced with a scalpel. 
Afterwards, cells were washed in PBS and th  i cubated in 
Accutase (Sigma-Aldrich, Stockholm, Swe en) at 37°C for 
20  min. They were rotated every 5 min o prevent sedimen-
tation. Finally, cells were passed 2–3 times through an 18 G 
needle before being filtered through a 100 µm nylon mesh. 
The single cell suspension was put in cell culture flasks with 
MSC Expansion Media.
Cell culturing
Tumor-derived cells were grown adherently n MSC Expan-
sion Media supplemented with Antibiotic–Antimycotic 
solution (AAS, Sigma-Aldrich) in cell culturing flasks at 
37 °C and 5 % CO2. Half of the medium was changed 1–3 
times per week. Cells at 70–100 % confluency were pas-
saged using Accutase.
Flow cytometry
Culture-derived cells at passage 2–4 w re stained with 
the following monoclonal antibod es; Brilliant Violet 421-
CD73 (AD2), Alexa Fluor 700-CD90 (5E10, both from 
Nordic BioSite, Täby, Sweden), PE-CD105 (266), PE-Cy5-
HLA-ABC (G46-2.6), FITC-CD14 (M5E2), FITC-CD19 
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Two-way ANOVA, where p < 0.05 was considered statisti-
cally significant. Linear regression analysis was performed 
correlating the survival time of patients to % total MSC in 
bulk culture or CD90+ c lls in bulk culture or CD90− e ls 
in bulk culture in all possible combinatorial forms. A p value 
lower than 0.05 was considered to be significant.
Results
Cells with MSC marker expression profile are present 
in human primary brain tumor cultures
Tumor specimens from 14 different glioma patients grown 
adherently in vitro and displayed a fibroblastic morphology 
consistent with MSCs (Fig. 1a–c). All 14 tumor samples 
were grown as bulk cultures. In all of these cultures, large 
numbers of spindle shaped cells with a morphology fully 
compatible with MSCs were observed attached to the plastic 
surface of the culture flask. Cells in bulk cultures were eas-
ily expandable, however, since we aimed for sorting at the 
lowest passage number possible, bulk cultures were never 
passaged more than a few times. We then assessed, by flow 
cytometry, whether cells fulfilling the consensus marker 
expression profile for MSCs are present in human gliomas.
At passage 2–4, all tumors contained a small subpopula-
tion of cells expressing the full MSC phenotype, as analysed 
by flow cytometry (Fig. 1d–f). Numerous cells displaying 
the full MSC consensus marker panel except for CD90 
were detected. The fraction of MSC-like cells relative to the 
total number of cells in culture varied within a wide range 
(Table 1 ; Fig. 1d–f). Notable was that in the majority of the 
tumors, the number of cells displaying the CD90− phenotype 
was larger than the CD90+ population. Routine pathological 
diagnosis revealed that the tumor with the noticeably high-
est amount of MSC-like cells was a gliosarcoma. Another 
interesting finding was that the low-grade astrocytoma (AC-
45) contained notably fewer MSC-like cells than most of 
the high-grade GBMs, however no correlation was observed 
between patient survival and the % of MSC-like cells in the 
tumor (data not shown).
MSC phenotype-expressing cells isolated from human 
brain tumors can differentiate into osteoblasts and, to 
some extent, adipocytes and chondrocytes
Next, we determined if the cells expressing MSC markers 
had the capacity to differentiate into adipocytes, osteoblasts 
and chondrocytes. Cells were sorted using FACS according 
to the consensus criteria defined by ISCT. Two populations 
from each tumor were isolated, one expressing the defined 
MSC phenotype and one expressing the defined phenotype 
except CD90. Sorted cells from only two different tumors 
Stained adipocytes and osteoblasts were analyzed w th 
a Nikon Diaphot 300 and a Nikon D70 (both from Niko , 
Yurakucho, Tokyo, Japan). Chond ocy e pellets were na-
lyzed with an Olympus BX61 and an Olympus DP72 (both 
from Olympus, Shinjuku, Tokyo, Japan).
RNA-sequencing extraction and gene analysis 
measurements
Total RNA from GBM-47 (passage number 2); GBM-48 
(passage number 2); GBM-47-deriv d MSC-like CD90− 
cells (passage number 8); GBM-48-derived MSC-like 
CD90 − cells (passage number 5); GBM-47-derived MSC-
like CD90+(passage number 10); GBM-48-derived MSC-
like CD90+(passage number 6); U87 primar  GBM cell 
line (passage number 30) and human bon -marrow derived 
MSC (hBM-MSC, passage number 1, from a 61 years old 
healthy male donor) was isolated by using RNAesay (Qia-
gen) with DNase treatment. RNA was extracted according to 
manufacturer instructions and their conc ntration wa  deter-
mined spectrophotometrically by Nano rop-ND 1000 spec-
tophotometer (Nanodrop). RNA quality w  analyzed using 
a Bioanalyzer (Agilent) and samples with a RNA integrity 
greater than seven were further analyzed. Subsequent RNA 
amplification and analysis were largely performed as pre-
viously reported in [16, 17 ] except that librarie  were pre-
pared using TruSeq Stranded mRNA Kit for NeoPr p from 
Illumina.
ELISA
Sorted tumor-derived stromal ce ls at passage 10–13 were 
analyzed for VEGF and PGE2 production using ELISA. 
1  × 10 5 cells/well were plated in  24 well plate and gr wn 
in 1 ml MSC Expansion Media for 24 h. Supernatants were 
collected, centrifuged and stored at −80  °C prior to analysis. 
VEGF levels were determined us ng the Human VEGF Duo-
Set kit (R&D Systems). PGE2 levels were determined using 
the Prostaglandin E2 EIA kit (Cayman Chemical Company, 
Larodan Fine Chemicals, Malmö, S de ). Experiments 
were performed in duplicate on three separate occasions.
Statistical analysis
The RNA sequencing data processi g was performed 
using the analysis pipe line method described in SCAN-B 
article [16 ]. Thus, after the first filtering processes, only 
the mRNAs showing differential expression be ween dif-
ferent groups are taken for furt er analysis. To compare 
the mRNA expression profile between the 2 GBM-derived 
MSC groups, CD90− and CD90+ cells, simple ttest was 
used and a p value <0.01 was considered significant. The 
VEGF and PGE2 production analysis was erformed using 
1 3
J Neurooncol (2017) 131:245–254 247
Possible adipocyte differentiation was only detected in 
the CD90− population of GBM-47 (Fig. 2a). In the CD90+ 
population, and in the sorted cells from GBM-48, the cells 
were clearly changed by the adipogenic differentiation 
were able to proliferate in vitro and were thus analyz d fur-
ther. Before sorting, cells had been assaged for 2–4 t mes 
and after sorting these cells were again passaged for a maxi-
mal total passage number of 14.
Fig. 1 In vitro images of 
adherently grown a BM-MSCs, 
b glioma-derived MSC-like 
CD90 − cells and c glioma-
derived MSC-like CD90+ cells. 
Scale bar 500  µm. d BM-MSCs 
and culture-derived tumor cells 
from e GBM-47 and f GBM-48 
were analyzed and sorted for 
MSC markers with flow cytom-
etry. Cells were stained for 
markers defining MSCs (CD73, 
CD90, CD105 and HLA class 
I). Doublets, dead cells and cells 
expressing lineage negative 
markers (CD14, CD19, CD34, 
CD45 and HLA-DR) were used 
as a cocktail in Lin TO-PRO-1 
and have already been excluded
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GBM-47 formed chondrocytes (Fig. 2c), as assessed by 
aggrecan immunoreactivity, whereas the corresponding 
populations from GBM-48 only showed weak aggrecan 
expression (data not shown).
stimulation but no clear lipid vacuole staining was visible. 
Further on, all sorted cells, even the ones lacking CD90, 
had the capacity to differentiate into osteoblasts (Fig. 2b). 
Finally, both the CD90− and CD90+ population from 
Table 1 Fourteen human brain tumors and BM-MSCs analyzed for MSC marker expression using flow cytometry
Sample Sex Age 
(years)*
Diagnosis Grade Passage at 
analysis
MSC** to total 
cell ratio in 
culture (%)
CD90 − MSC 




BM-MSC – – – – 5 97.1 – –
AC-45 m 31 Astrocytoma II 4 0.539 3.73 24
ODG-44 f 49 Oligodendro-gliomaIII 2 3.62 35.3 ***
GBM-40 m 75 GBM IV 4 13.6 85.4 9
GBM-43 m 78 GBM IV 4 1.43 21.3 9
GBM-46 m 56 GBM IV 3 0.417 4.03 3
GBM-47 m 58 GBM IV 2 7.19 5.58 16
GBM-48 m 71 GBM IV 2 29.6 63.5 1
GBM-49 f 69 GBM IV 3 1.33 13.7 10
GBM-51 m 60 GBM IV 2 1.68 0.525 27
GBM-52 m 76 GBM IV 4 4.13 6.33 1
GBM-53 m 62 Gliosarcoma IV 2 34.3 48.7 17
GBM-54 m 69 GBM IV 2 11.0 27.4 11
GBM-55 f 62 GBM IV 4 1.94 0.203 8
GBM-56 m 45 GBM IV 4 0.0183 2.63 ***
*Age at the time of surgery
**Positive for CD73, CD90, CD105, HLA class I; negative for CD14, CD19, CD34, CD45, HLA-DR
***Alive
Fig. 2 Sorted tumor-derived stromal cells were differentiated into  
adipocytes, b osteoblasts and c chondrocytes. Light microscope images 
reveal lipid vacuoles in adipocytes and calcium deposits in osteoblasts. 
Epifluorescent images show aggrecan stai ing (red) on chondrocytes. 
Nuclei are blue. Scale bar 100  µm in a and 500µm in b and c
 
1 3
J Neurooncol (2017) 131:245–254 249
Discussion
Malignant gliomas with a mesenchymal gene expression 
profile are associated with an invasive growth pattern and 
short survival and recurring tumors often display a mesen-
chymal phenotype [18 , 19]. In this study, we analyzed 14 
primary human malignant gliomas and conclude that all of 
them harbor cells expressing surface markers defined by 
ISCT [7].
By employing a stricter flow cytometric analysis, adher-
ing to the ISCT criteria, and by, for the first time for this par-
ticular purpose, sorting cells, we expand on previous reports 
of MSC-like cells in malignant glioma [13 ]. We found that 
malignant gliomas harbor two distinct MSC-like cell popu-
lations, differing in their CD90 expression. Although a dif-
ferent tri-mesenchymal differentiation capacity was noticed 
between CD90+ and CD90− populations, as indicated by 
adipocyte differentiation only in cells lacking CD90, this 
data is preliminary and further experiments, optimizing the 
expansion of MSC clones from a larger number of tumor 
samples, is warranted in order to confirm if the absence of 
adipocyte differentiation is a distinctive feature of CD90+ 
cell population.
In most tumor samples, the CD90− popula ion was larger 
than the CD90+ population. Both populations were expand-
able and retained their proliferative capacity in vitro. Unfor-
tunately, these cell populations were difficult to detach 
from the plastic surface during the first passages and we 
could only perform complete studies in cells derived from 
2 patients. The number of MSC-like cells compared to the 
total number of cells (MSC to total cell number in culture in 
Table 1 ) following 2–4 passages in vitro showed a very wide 
variation. Yet, the present study was not designed in order to 
quantify the ratio of MSC-like cells within glioma stroma. 
Interestingly though, the tumor with the highest proportion 
of MSC-like cells was a gliosarcoma, a GBM subtype with 
a clear mesenchymal component [14].
To confirm that the two MSC-like cell populations CD90+ 
and CD90− constitute two distinct cell populations, we ana-
lyzed their gene expression profile. Although we were lim-
ited in the number of samples, the mRNA expression profiles 
clearly support the notion that these are, in fact, two different 
populations. Intriguingly, although the cell surface expres-
sion of CD90 separates these populations, their CD90 mRNA 
expression profile did not differ, suggesting that cell surface 
glycoprotein CD90 could be either engulfed from the surface 
due to a cell reaction to some environmental stimuli, thus 
becoming undetectable on the surface or, that CD90− cells 
react to some stimuli and overexpress CD90 as a response 
to the stimuli. In vitro angiogenic stimuli, for example, 
generate hM-MSC lacking CD90 expression [20] whilst 
We conclude that cells display g a complete MSC phe-
notype can be present in human brain tumor specimens. 
MSC-like cells lacking CD90 isolated from pr mary human 
brain tumors could differentiat  into osteoblas s, adipocytes 
and chondrocytes, whereas the corresponding cells express-
ing CD90 only formed osteoblasts and chondrocytes.
Differential mRNA expression in CD90+ and CD90− 
MSC-like populations
Differentially expressed gene (DEG) analysis of th  tran-
scriptional profile associated with the different cell types here 
analyzed (GBM, GBM-derived MSC, U87 and hBM-MSC) 
revealed that there is a different mRNA expression profile 
between the 2 sorted MSC-like cells, CD90+ and CD90− 
(Fig. 3a). A t test was subsequently performed to identify 
differentially expressed gen s b tween CD90− and CD90+ 
cell types, this resulted in total, 211 genes (135 up regulated 
and 76 down regulated in CD90+ cell lines). Differentia ly 
expressed genes were next subjected to functional ann tation 
analysis using Metacore web-based software (https://portal.
genego.com/) and results show that, mongst the up regulated 
genes in the CD90+ cell lines, 50 % were enriched for the 
glutathione metabolism; 25 % were enriched for the cyto-
skeleton remodeling and 8.3 % for cell adhesion. Amongst 
the down-regulated genes, 46.7 % were involved in apoptosis 
and survival; 33.3 % were involved in the immune response 
and 13.3 % in cell adhesion (Fig. 3b–d). Interesting y, and 
although cell surface expression f CD90 clearly separa s 
two distinct populations of glioma-derived MSC-like cel s, 
the CD90 mRNA expression profile was not significantly dif-
ferent between these two cell populations and thus, was ot 
taken into account for the different analysis (Fig. 3).
The CD90− MSC-like population produces more VEGF 
and PGE2 compared to its CD90
+ counterpart
The two cell populations that were expandabl  following 
cell sorting were analyzed for VEGF a d PGE2 pro uc-
tion. The results show that the CD90− cells from two GBMs 
secreted significantly higher levels of VEGF compared 
to the CD90+ cells from the same tumors (mean 166 and 
58.6 pg/ml, respectively, p < 0.01; Fig. 4a).
The CD90− population from GBM-47 also produced 
considerably more PGE2 compared to the CD90
+ popu-
lation from the same tumor (mean 9830 and 234 pg/ml, 
respectively, p < 0.01). Similar, the PGE2 production of
the CD90− population from GBM-48 produced signifi-
cantly more PGE2 compared to the CD90
+ population from 
the same tumor (mean 213 and 55.5 pg/ml, respectively, 
p < 0.05; Fig. 4b).
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vascularization and immunosuppression [15 ]. However, 
CD90 has also been reported to be a tumor suppressor [25]. 
The present study might lend some support to the latter, as 
we found that the MSC-like CD90− cel s could be produc-
ing elevated levels of VEGF compared to the CD90+ cells 
from the same tumors. If confirmed, this could indicate that 
the CD90− population of glioma-derived MSC-like cells 
might be more actively involved in tumor angiogenesis than 
the CD90+ subpopulation. In addition to its critical role 
in tumor angiogenesis, VEGF has been reported to attract 
MSCs themselves to glioma cells [3]. Furthermore, VEGF 
has been reported to stimulate MSC proliferation [26], indi-
cating that autocrine mechanisms might function to stimu-
late MSC recruitment and proliferation within glioma.
The immunosuppressive function of BM-MSCs is well 
characterized and utilized clinically [27]. Among the key 
immunoactive factors expressed by MSCs is prostaglandin 
E 2 (PGE2) [28], which has been shown to induce immu-
nosuppression within tumors [15 , 29]. Beca se of tech-
nical reasons, we were only able to expand FACS sorted 
cells from two glioblastoma, which severely restricted their 
further analysis. However, interestingly, the CD90− MSC-
like cells secreted markedly higher amounts of PGE2 com-
pared to the CD90+ cells. PGE2 is a molecule known to be 
important for BM-MSC-induced immunosuppression [30 ], 
suggesting that glioma-derived MSC-like cells, and the 
CD90 − subpopulation in particular, may actively contribute 
to the glioma immunosuppression.
overexpression of surface cell markers upon inflammatory 
stimuli has been already reported for neurotrophic re ep-
tors [21]. In addition, mechanical st ess has been reported o 
decrease CD90 cell surface glycoprotein n MSC [22]. Sin e 
little mechanical stress was performed during culturing, and 
the number of passages were l w when mRNA express on 
analysis was performed, this hypothe is is quite unlikely. 
Alternatively, the CD90 mRNA could suffe  any type of post-
translational preventing the receptor from being visible on the 
surface [23, 24]. Future experiments for a further de p char-
acterization of CD90+ and CD90− populations are nvisag d.
Likewise, the functional significance of CD90 expres-
sion, or lack thereof, on glioma-derived MSC-like cells 
needs further investigations. Previous s udies h ve s g-
gested that CD90+ pericytes within gliomas promote 
Fig. 4 a VEGF and b PGE 2 production in vitro by two different cell 
populations from each of two GBMs. The CD90− populations from 
GBM-47 and GBM-48 produce higher levels of both VEGF and PGE2 
compared to the CD90+ populations from the same tumors. 1 × 10 5 
cells were g own in 1 ml MSC Expansion Media for 24 h and the 
supernatants were analyzed with ELISA. Each experiment was per-
f rmed three times in duplicate and VEGF data from both tumors was 
pooled t gether
 
Fig. 3 a Heatmap of genes differentially expressed in RNA-sequenc-
ing analysis performed on GBM-47; GBM-48; GBM-47/48-derived 
MSC-like CD90− cells; GBM-47/48-derived MSC-like CD90+; U87 
primary GBM cell line and bone-marrow deriv d MSC how glioma-
derived MSC-like CD90− and D 0+ cells gene expression patterns to 
be different (p < 0.01, paired Student’s t test). CD90+ cells clustering 
with U87 and later with hBM-MSC, may possibly reflect a similar 
pluripotency stage. b Unsupervised hierarchical sample clustering 
between glioma-derived MSC-like CD90− and CD90+ ce ls (p < 0.01, 
paired Student’s t test). c Significantly up-regulated canonical path-
ways within the transcriptional profile from the MSC-like CD90+ cells 
versus MSC-like CD90− cells. d Significantly down-regulated canoni-
cal pathways within the transcriptional profile from the MSC-like 
CD90 + cells versus MSC-like CD90− ce ls

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